ing of the radio-opaque agents to peptides.
Therefore, we must reasonably wonder if the appearance of interfering peaks in the electropherograms is only a coincidence of the unexpected elution times and absorbance spectra of the iodinated radio-opaque media with the stated elution times and absorbance spectra of the proteins (6 ) or a result of binding to the signal reagent.
We conclude that blood must not be collected for protein electrophoresis by CZE from patients who have received contrast media during the preceding 2-6 days. This time period has been described for some radioopaque agents by Bossuyt et al. (6 ) and should be established for new contrast media according to their elimination times from blood. In addition, in questionable samples for paraprotein with negative immunofixation, we recommend the desalting procedure as described.
María Luisa Arranz-Peñ a * Manuel González-Sagrado Ana María Olmos-Linares Nuria Fernández-García Francisco Javier Martín-Gil
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Stability of Clinical Chemistry Analytes in Blood Collection Devices
To the Editor: During the AACC Annual Meeting in New Orleans in July 1999, Greiner Meditech Inc. (Bel Air, MD), distributed sample packages with labeling claiming that their serum and plasma Vacuette ® blood collection tubes with clot activator and separation gel for clinical chemistry analyses are capable of maintaining the stability of all analytes during storage for 48 h without affecting the serum or plasma values (1 ) . I found similar 48-h stability claims for the Vacuette blood collection devices on Greiner's Web sites in the United States and Europe (2, 3 ) . In addition, colleagues in laboratories in Spain had received Greiner Vacuette product information with universal 48-h stability claims (4 ) . Data supporting the claims described above were not provided in any of the above instances and could not be found during an extensive literature search.
The 48-h stability claim is presented in a way that may be interpreted by many users of this product as being generally applicable to all serum and plasma chemistry analytes without limitations. Although many commonly measured analytes are stable in serum or plasma up to 48 h, natural degradation and/or absorption of compounds by synthetic barriers, such as polymer separating gels, in tubes can occur. In one study, in three different blood collection tubes with inert barriers, phenobar-bital and carbamazepine concentrations decreased significantly after 24 h (5 ) . Another study found significant decreases of 5.9 -64.5% in phenytoin, phenobarbital, lidocaine, quinidine, and carbamazepine as a function of both time and sample volume when serum was stored in certain serum separator blood collection tubes (6 ) . These decreases were attributed to absorption of the drugs by the barrier gels. Several other studies have also highlighted the potential interference of separation gels with therapeutic drug monitoring (7) (8) (9) (10) (11) . In a report by Williams et al. (12 ) , serum alanine aminotransferase decreased 6% in separated serum stored 2 days at 4°C and 20% at 22°C. Storage of blood in plasma separator tubes overnight can cause differences in urate concentration that are likely to affect clinical interpretation (13 ) .
Several European experts in clinical chemistry and the NCCLS have published specimen handling recommendations to reduce preanalytical variables (14 -16 ) . These recommendations differ considerably from the ones made by Greiner regarding storage of their products (1-3 ) . The degradation of certain chemistry analytes or their absorption by tube components can be a significant source of error in the preanalytical phase of laboratory testing. Greiner's claim of universal 48-h stability appears to be incompatible with the experience described in the literature and currently recommended laboratory standards. Hospital and reference laboratories that rely on the claim and store specimens for 48 h may be unaware of the potential effects of the preanalytical phase of testing.
Blood collection devices and their proper handling play an integral part in routine laboratory analyses. Technical improvements that have been made to these devices in the past (e.g., separating gel) have generally led to a reduction of preanalytical variability and an improved quality of the overall testing process. New claims made by tube manufacturers to further improve their products should therefore be supported by the Clinical Chemistry 46, No. 5, 2000 appropriate clinical documentation and should be in agreement with generally accepted laboratory standards.
Friedel E. Krapf
IML Immunologisch-Medizinisches Labor Am Tower 11 D-90475 Nü rnberg, Germany
Fax 49-9128-920381 E-mail iml@labor-krapf.de
A representative of Greiner VACU-ETTE ® North America responds:
To the Editor: We at Greiner VACUETTE ® North America agree with Dr. Krapf. Our statement about analyte stability was an unintentional misinterpretation of an original statement about the stability of our gel barrier. What we meant is that our gel barrier is stable for up to 48 h. Our product package insert does not make any mention of analyte stability.
We apologize if we misled anyone and have taken steps to fix current literature and our web sites, and to correct any misunderstanding. We look forward to continued feedback from any potential user or current customer in the marketplace. We believe the only way Greiner can continue to provide needed products and innovations is for us to actively listen to all of the feedback.
Douglas L. Harris
Greiner-VACUETTE ® North America
PO Box 943 Bel Air, MD 21014 E-mail greinermed@aol.com
